When was ixazomib launched in China? Have you entered medical insurance?

Ixazomib was launched in China in December 2016 and has been included in medical insurance and can be reimbursed. For specific reimbursement policies, please refer to local policies. Ixazomib is a proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one prior therapy.

Based on population pharmacokinetic analysis, coadministration of ixazomib with a strong inhibitor of CYP1A2 did not result in clinically meaningful changes in the systemic exposure of ixazomib. IxazomibNeitherCYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4/5 are also not time-dependent inhibitors. Ixazomibdoes not induce CYP1A2, CYP2B6 and CYP3A4/5 activities or corresponding immunoreactive protein levels. Ixazomib is not expected to inhibit or induce drug interactions via CYP.

Ixazomibis a low-affinity substrate for P-gp. Ixazomib is not a substrate for BCRP, MRP2, or hepatic OATPs. Ixazomib >, OCT2, OAT1, OAT3, MATE1 or MATE2-K inhibitors. Ixazomib is not expected to cause transporter-mediated drug-drug interactions. After a single oral dose14C-ixazomibIn 5 patients with advanced cancer, 62% of the administered radioactivity was excreted in the urine, and 22% was excreted in the feces. Unaltered ixazomib accounted for 3.5% of the administered dose recovered in urine. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.